Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Bayer to improve...

    Bayer to improve disease diagnosis, drug design via use of AI

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-10-02T09:32:19+05:30  |  Updated On 2 Oct 2019 9:32 AM IST
    Bayer to improve disease diagnosis, drug design via use of AI

    Germany's Bayer has been testing how the technology can help diagnose complex or rare conditions, hasten drug development and more.


    New Delhi: Drugmakers have embraced artificial intelligence - using computers to analyze reams of data and then make predictions or recommendations.


    Germany's Bayer has been testing how the technology can help diagnose complex or rare conditions, hasten drug development and more.


    The aspirin-creator has partnered with startups and other tech companies to develop software and apps to speed diagnosis and guide treatment. The company is working with hospitals, academic researchers and others to compile everything the AI software needs to "learn" before it analyzes a patient's condition. That includes information on disease causes, symptoms and progression, plus many past patients' test results, doctor reports and scanned images.


    Also Read: Bayer, Monsanto India mega-merger worth USD 63 billion gets clearance from NCLT

    The Associated Press recently interviewed Angeli Moeller, who heads artificial intelligence projects across Bayer's pharmaceutical business. Answers have been edited for clarity and brevity.


    Q: Why use partners for developing AI software and apps?


    A: These areas are so new and so exploratory that you just wouldn't get there on time alone. We partner with companies that have that expertise and can accelerate development. We believe we will save a couple of years.


    Q: How is Bayer using AI?


    A: We're looking at cardiovascular disease, oncology and women's health. Our focus is on diagnosis but also on digital therapeutics, where you're using the technology to recommend a patient make a change in behaviour to improve their health, or you're recommending medication changes.


    Q: How would Bayer and other drugmakers working on AI software get hospitals or insurers to pay for using it?


    A: We would show that the software does what it says. It becomes cost-effective and attractive for them when we can prove the improved outcomes with our app.


    Q: How are you using AI to improve the design and patient testing of experimental drugs?


    A: When developing a new drug, we can model how it will behave in a cell in combination with other drugs the patients might be taking. We're looking at how we can identify the right patients and sites to run our clinical trials. We would be able to run shorter studies and show where the medication is the right one for those patients earlier.


    Q: How might this eventually affect doctors and patients?


    A: Everything we're doing in our artificial intelligence program is for decision support because we want the doctor to make the decision on treatment. In the doctor's office, you would have a computer dashboard showing recommendations, but the really high-powered computing would happen somewhere else. What's most important for patients is that they're still in control of their treatment.


    Q: How long will it be before this is helping average patients?


    A: It's probably going to take two years before it really hits mainstream medical practice. Getting the technology to the patient is still the hard part.


    Also Read: Bayer to streamline structure of Management Board to cut costs
    AIAI softwareartificial intelligenceBayerDigital Therapeuticsdisease diagnosisdrugdrug designDrugmakersGermanyoncology
    Source : AP

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok